Adagene Presents Clinical Data Co Says Demonstrates Strong Safety, Early Signals Of Efficacy In Cold Tumors Including Pancreatic And Ovarian Cancers For Anti-CTLA-4 Monoclonal Antibody, ADG116, At ESMO-IO 2021

by | Dec 6, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.